V Taucher1, H Mangge2, J Haybaeck3. 1. Institute of Pathology, Medical University Graz, Auenbruggerplatz 25, A-8036, Graz, Austria. 2. Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Graz, Auenbruggerplatz 25, A-8036, Graz, Austria. 3. Institute of Pathology, Medical University Graz, Auenbruggerplatz 25, A-8036, Graz, Austria. johannes.haybaeck@medunigraz.at.
Abstract
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with a dismal prognosis for which new therapeutic strategies are desperately needed. Non-coding RNAs (ncRNAs), especially microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), may yield new therapeutic concepts for the treatment of PDAC. A vast number of miRNAs, including the well-studied miR-21, miR-155 and miR-34, has been shown to regulate PDAC growth, invasion and metastasis in vitro and in vivo by targeting members of key signaling pathways. In addition, other miRNAs and lncRNAs, such as HOTTIP and MALAT-1, have been shown to influence the malignant behavior of PDAC cells. METHODS: Here, we discuss several ncRNAs that may be used either as new therapeutic agents or as targets of new therapeutic agents. Furthermore, we discuss the problem of proper delivery of nucleotide-based agents and novel methods that may be used to circumvent this problem. CONCLUSIONS: Although the number of reports addressing the role of ncRNAs in PDAC virtually grows by the day, there are still many steps to be taken before the application of ncRNA-based therapies will become reality in clinical practice.
BACKGROUND:Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with a dismal prognosis for which new therapeutic strategies are desperately needed. Non-coding RNAs (ncRNAs), especially microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), may yield new therapeutic concepts for the treatment of PDAC. A vast number of miRNAs, including the well-studied miR-21, miR-155 and miR-34, has been shown to regulate PDAC growth, invasion and metastasis in vitro and in vivo by targeting members of key signaling pathways. In addition, other miRNAs and lncRNAs, such as HOTTIP and MALAT-1, have been shown to influence the malignant behavior of PDAC cells. METHODS: Here, we discuss several ncRNAs that may be used either as new therapeutic agents or as targets of new therapeutic agents. Furthermore, we discuss the problem of proper delivery of nucleotide-based agents and novel methods that may be used to circumvent this problem. CONCLUSIONS: Although the number of reports addressing the role of ncRNAs in PDAC virtually grows by the day, there are still many steps to be taken before the application of ncRNA-based therapies will become reality in clinical practice.
Authors: Manuel Beltran; Isabel Puig; Cristina Peña; José Miguel García; Ana Belén Alvarez; Raúl Peña; Félix Bonilla; Antonio García de Herreros Journal: Genes Dev Date: 2008-03-15 Impact factor: 11.361
Authors: Yiwei Li; Timothy G VandenBoom; Dejuan Kong; Zhiwei Wang; Shadan Ali; Philip A Philip; Fazlul H Sarkar Journal: Cancer Res Date: 2009-08-04 Impact factor: 12.701
Authors: Christophe Van Neste; Alexander Laird; Fiach O'Mahony; Wim Van Criekinge; Dieter Deforce; Filip Van Nieuwerburgh; Thomas Powles; David J Harrison; Grant D Stewart; Tim De Meyer Journal: Cell Oncol (Dordr) Date: 2017-01-10 Impact factor: 6.730
Authors: Nina J Chu; Robert A Anders; Elana J Fertig; Minwei Cao; Alexander C Hopkins; Bridget P Keenan; Aleksandra Popovic; Todd D Armstrong; Elizabeth M Jaffee; Jacquelyn W Zimmerman Journal: Cancer Prev Res (Phila) Date: 2020-05-14
Authors: Antonella Caivano; Francesco La Rocca; Vittorio Simeon; Marco Girasole; Simone Dinarelli; Ilaria Laurenzana; Angelo De Stradis; Luciana De Luca; Stefania Trino; Antonio Traficante; Giovanni D'Arena; Giovanna Mansueto; Oreste Villani; Giuseppe Pietrantuono; Luca Laurenti; Luigi Del Vecchio; Pellegrino Musto Journal: Cell Oncol (Dordr) Date: 2016-10-19 Impact factor: 6.730